Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure
Young women have an increased risk of venous thromboembolism (VTE) during hormonale exposure (estrogen-containing pill or pregnancy). In order to detect women at higher risk of VTE during hormonal exposure, thrombophilia testing is often performed in order to adapt contraception methods and/or to increases thromboproph
| Condition(s) | Venous Thromboembolic Disease |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Young women have an increased risk of venous thromboembolism (VTE) during hormonale exposure (estrogen-containing pill or pregnancy). In order to detect women at higher risk of VTE during hormonal exposure, thrombophilia testing is often performed in order to adapt contraception methods and/or to increases thromboprophylaxy during pregnancy. However, such practice is probably not accurate nor discriminent. Indeed, there are evidence that the impact of the familial history of VTE might be stronger than that of detectable inherited thrombophilia. The "FIT-H" study is a cross-sectional study comparing the prevalence of previous venous thromboembolism in first-degree relatives of women (propositi) who had a first episode of venous thromboembolism in association with hormonal exposure with the |
| Who can participate | Eligibility criteria: \- Propositi with objectively confirmed proximal deep vein thrombosis (i.e. ultrasonography) or pulmonary embolism (i.e. lung scanning) in women (18 to 50 years) while on hormonal exposure. Inclusion criteria * First-degree relatives (biological parents, brothers, sisters, children) of women of childbearing age 18-50 years (propositus) with a first MVTE in the hormonal setting and matched control women in the same hormonal setting who have never had MVTE, consenting to first-degree relatives being contacted to participate in the present study. * Written consent from propositi and family members. Exclusion criteria * First-degree relatives whose propositus received preventive antithrombotic medication during pregnancy or contraception. * Family members of propositus wh |
| Ages | 16 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | University Hospital, Brest |
| Locations | Brest, France; Brest, France; Clermont-Ferrand, France; Morlaix, France; Paris, France; Rennes, France (+2 more sites) |
| Start date | 2017-10-24 |
| NCT ID | NCT03206372 |
| Official listing | https://clinicaltrials.gov/study/NCT03206372 |